The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

SARS-CoV-2 (C.37: L452Q, F490S) Spike Glycoprotein (S1) RBD, His-Tag (HEK293)

$573.70$2,186.66 excl. VAT

LAMBDA VARIANT

Recombinant SARS-CoV-2 (C.37: L452Q, F490S) receptor binding domain (RBD) including amino acid changes L452Q and F490S relative to Wuhan-Hu-1. The protein was produced in HEK293 cells and purified from culture supernatant. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

REC31992_SDS-PAGE
SDS-PAGE: Coomassie-stained SDS-PAGE showing purified SARS-CoV-2 C.37 RBD.

SARS-COV-2 (C.37: L452Q, F490S) SPIKE GLYCOPROTEIN (S1) RBD, HIS-TAG (HEK293)

Recombinant SARS-CoV-2 (C.37: L452Q, F490S) receptor binding domain (RBD) including amino acid changes L452Q and F490S relative to Wuhan-Hu-1. The protein was produced in HEK293 cells and purified from culture supernatant. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

 

PRODUCT DETAILS – SARS-COV-2 (C.37: L452Q, F490S) SPIKE GLYCOPROTEIN (S1) RBD, HIS-TAG (HEK293)

  • SARS-CoV-2 Lambda variant (C.37: L452Q, F490S) spike RBD (Accession: 7EAM_A, L452Q, F490S)
  • SARS-CoV-2 (C.37) RBD contains L452Q, F490S mutations relative to Wuhan Hu-1.
  • Expressed in HEK293 and purified by affinity chromatography.
  • Presented in DPBS at

 

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The sequence WIV04/2019, belonging to the GISAID S clade / PANGOLIN A lineage / Nextstrain 19B clade, is believed to be the original sequence infecting humans (Zhukova et al., 2020). However, there are many thousands of variants of SARS-CoV-2 (Koyama et al., 2020) and subtypes of the virus can be placed into much larger groupings such as lineages or clades. WHO have designated variants of concern as Alpha (United Kingdom), Beta (South Africa), Gamma (Brazil) and Delta (India), depending on location of earliest documented samples.

SARS-CoV-2 C.37 or Lambda variant was first detected in Peru in August 2020. The Lambda genome has the following amino acid mutations, all of which are in the virus’s spike protein code: G75V, T76I, Δ246-252, L452Q, F490S, D614G and T859N. It has been shown to be more resistant to neutralizing antibodies compared to other strains and may be more infectious and resistant to vaccines than the Alpha and/or Gamma variants. Studies have found that sera from the Pfizer-BioNTech vaccine remain high reactivity toward the receptor binding domain (RBD) of Delta variant while it drops dramatically toward that of Lambda variant. This may be correlated with a drop in the overall titer of antibodies of Pfizer-BioNTech vaccinated individuals after 6 months. The data suggests a potential surge of Lambda variant in near future (Liu et al., 2021).

 

REFERENCES

  • CDC. SARS-CoV-2 Variant Classifications and Definitions.
  • Haolin Liu, Pengcheng Wei, Qianqian Zhang, et al. The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines. bioRxiv. August 26, 2021.
    Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 2020 Jul 1;98(7):495-504.
  • Zhukova A, Blassel L, Lemoine F, Morel M, Voznica J, Gascuel O. Origin, evolution and global spread of SARS-CoV-2. C R Biol. 2020 Nov 24. doi: 10.5802/crbiol.29.
  • WHO. Tracking SARS-CoV-2 variants.

Certificate of analysis
Certificate of analysis – Biotin Conjugate
Safety datasheet
Safety datasheet – Biotin Conjugate

Dry Ice

You may also like…